YD Bio Limited Ordinary Shares (YDES) Stock Price & Analysis
YD Bio Limited Ordinary Shares (YDES) — MoonshotScore 29/100 (Weak band), calculated Oct 26, 2026. Price $4.95 (+16.75%), as of the Oct 23, 2026 trading session; market cap $351M.
Educational signal · not a buy or sell recommendation · How to read this
YD Bio Limited Ordinary Shares · YDES · NASDAQ
YD Bio Limited Ordinary Shares is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. They are focused on cancer prevention medical diagnostics and the development of exosome-based therapeutics.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore v2 · YD Bio Limited Ordinary Shares (YDES)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but bottom-tier quality and stalling growth. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- Altman Z 36.73 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak |
The score moved from 28 in the stored Oct 24, 2026 snapshot to 29 in the current publication computed Oct 26, 2026 (+1); the largest pillar moves were Momentum +1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.95 | |
| Change on the day | +16.75% | |
| 52-week range | $1.70 – $20.07 | |
| Market capitalisation | $351M | |
| Shares traded on the day | 105.1K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for YD Bio Limited Ordinary Shares (YDES): Split View
38/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the YDES film — every key number, told as a short cinematic story
~2 min · open the film
What is YD Bio Limited Ordinary Shares (YDES), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. YD Bio Limited Ordinary Shares (YDES) is listed on NASDAQ. It employs 14 people and is led by Ethan Shen. The market values it at $351M.
What are the financial strengths and risks for YD Bio Limited Ordinary Shares (YDES)?
Short answer
The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 36.73 · Piotroski F 2. Trailing ratios: ROA -60.3% · current ratio 5.88 · earnings yield -2.9% · free-cash-flow yield -2.7%.
How does YD Bio Limited Ordinary Shares compare with its peers?
Short answer
YD Bio Limited Ordinary Shares's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $7.94 Oct 26, 2026 | $612M | 95 5-pillar Oct 26, 2026 | |
| $49.93 Oct 26, 2026 | $926M | 93 5-pillar Oct 26, 2026 | |
| $9.53 Oct 26, 2026 | $566M | 91 5-pillar Oct 26, 2026 | |
| $3.85 Oct 26, 2026 | $570M | 88 5-pillar Oct 26, 2026 | |
| $4.20 Oct 26, 2026 | $832M | 85 5-pillar Oct 26, 2026 | |
| $11.90 Oct 26, 2026 | $793M | 79 5-pillar Oct 26, 2026 | |
| $10.24 Oct 26, 2026 | $93.6M | 78 5-pillar Oct 26, 2026 | |
| $4.08 Oct 26, 2026 | $170M | 75 5-pillar Oct 26, 2026 | |
| $2.44 Oct 26, 2026 | $190M | 70 5-pillar Oct 26, 2026 | |
| $8.45 Oct 26, 2026 | $258M | 67 5-pillar Oct 26, 2026 | |
| $8.81 Oct 26, 2026 | $506M | 67 5-pillar Oct 26, 2026 | |
| $8.96 Oct 26, 2026 | $1.37B | 66 5-pillar Oct 26, 2026 | |
| YD Bio Limited Ordinary Shares (YDES) — this page | $4.95 | $351M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 9
- Identified insiders
- 3
- Purchases
- 3
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
YD Bio Limited Ordinary Shares Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the YDES research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for YDES?
YDES carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. YD Bio Limited Ordinary Shares is a clinical-stage biopharmaceutical company based in Taipei, Taiwan.
Is YDES a good stock to buy?
Stock Expert AI does not rate YDES buy, sell or hold. YD Bio Limited Ordinary Shares carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the YDES stock price today?
The last price recorded on this page for YD Bio Limited Ordinary Shares (YDES) is $4.95, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for YDES?
The main risks for YDES include the inherent uncertainties of clinical trials, the potential for regulatory delays or rejections, and competition from larger pharmaceutical companies with greater resources. As a small, clinical-stage company, YDES is also vulnerable to funding challenges and dependence on key personnel.
What are the key factors to evaluate for YDES?
YD Bio Limited Ordinary Shares (YDES) holds a MoonshotScore in the low range. Based in Taipei, Taiwan, providing access to a growing biotechnology hub. Not financial advice.
How frequently does YDES data refresh on this page?
YDES's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven YDES's recent stock price performance?
YD Bio Limited Ordinary Shares (YDES) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative exosome-based therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YDES overvalued or undervalued right now?
YD Bio Limited Ordinary Shares (YDES) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of YDES?
Fractional-share availability for YD Bio Limited Ordinary Shares (YDES) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 6 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $4.95 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T07:24:32.764Z. | |
px.change | Change on the day | +16.75% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $351M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:00.000Z. Captured from FMP at 2026-10-26T07:24:31.700Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.71 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 105.1K | FMP | Financial Modeling Prep (FMP) · quote | |
own.insiders | Insider transactions via FMP | 9 transactions · 3 purchases, 0 sales, 6 other transactions · 3 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 36.73 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
px.range52 | 52-week range | $1.70 – $20.07 | UNRECORDED | Stored company-profile observation — Captured 2026-10-20 | |
id.employees | Employees | 14 | UNRECORDED | Stored company-profile observation — Captured 2026-10-20 | |
id.ceo | Chief executive | Ethan Shen | UNRECORDED | Stored company-profile observation — Captured 2026-10-20 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -60.3% · current ratio 5.88 · earnings yield -2.9% · free-cash-flow yield -2.7% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 29 of 100 · Weak · pillars 17 / 91 / 53 / 21 / 69 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 28 (stored snapshot Oct 24, 2026) → 29 (current publication computed Oct 26, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.